Cetyltrimethylammonium bromide inhibits the metastasis of breastcancer to the lungs by inhibiting epithelial-mesenchymal transition  

作　　者：NING LI YANG CHEN YONGJIE YANG SHUHAN LYU YUE PAN 

机构地区：[1]State Key Laboratory of Fine Chemicals,Department of Pharmaceutical Sciences,School of Chemical Engineering,Dalian University of Technology,Dalian,China [2]Department of Pain Management,Shandong Provincial Hospital affiliated to Shandong First Medical University,Jinan,China [3]Department of Pharmacy,The First Affiliated Hospital of Zhengzhou University,Zhengzhou,China [4]Henan Key Laboratory of Precision Clinical Pharmacy,Zhengzhou University,Zhengzhou,China [5]Ningbo Institute of Dalian University of Technology,Ningbo,China

出　　处：《BIOCELL》2022年第6期1473-1482,共10页生物细胞（英文）

基　　金：This research was supported by 81803024(National Natural Science Foundation of China);DUT21LK23(Fundamental Research Funds for the Central Universities).

摘　　要：Breast cancer is a highly aggressive cancer in females. Metastasis is a major obstacle to the efficient andsuccessful treatment of breast cancer. Cetyltrimethylammonium bromide (CTAB) has anti-tumor effects on a varietyof tumors. We showed that CTAB inhibits the metastasis of breast cancer to the lungs both in vitro and in vivo.Epithelial-mesenchymal transition (EMT) is thought to be one of the major processes mediating breast cancermetastasis. We found that CTAB suppressed EMT and regulated the levels of the classical EMT markers E-cadherin,N-cadherin, vimentin, Snail and Twist1. Moreover, as a candidate anti-tumor agent, CTAB showed primary safety invivo. Taken together, our results suggest that CTAB inhibits the migration of primary breast cancer to the lungs. Ourfindings confirm the clinical potential of CTAB for the treatment of breast cancer by targeting EMT. CTAB may thusbe a promising novel anti-tumor drug for the treatment of breast cancer metastasis.

关 键 词：Migration EFFECTIVENESS Security EMT-TFs 

分 类 号：R73[医药卫生—肿瘤]